• Description
  • Programmes
  • Contact

Sectors: Environment, Innovation, New technologies, Research

Beneficiaries: Corporations, Research centres, SMEs

Regions: Balkans, Candidate countries, Developing countries, European Economic Area, European Union, Mediterranean countries, New Independant States, Switzerland

Category: Call for proposals

References:

To view this information, please connect.

Responsible: European Commission

Amorce:

This call for proposals aims to understand, demonstrate, and quantify the value of diagnostics and the obstacles to their adoption and use in the framework of a Standardised Care Network in order to combat antimicrobial resistance (AMR) by optimising antibiotic use in Europe

Priorities and funded actions:

TOPIC
Open:
– IMI2-2017-13-01: Assessment of the uniqueness of diabetic cardiomyopathy relative to other forms of heart failure using unbiased pheno-mapping approaches 
– IMI2-2017-13-02: Genome-Environment Interactions in Inflammatory Skin Disease
– IMI2-2017-13-03: The value of diagnostics to combat antimicrobial resistance by optimising antibiotic use
– IMI2-2017-13-04: Mitochondrial Dysfunction in Neurodegeneration
– IMI2-2017-13-05: Support and coordination action for the projects of the Neurodegeneration area of the Innovative Medicines Initiative
– IMI2-2017-13-06: A sustainable European induced pluripotent stem cell platform
– IMI2-2017-13-07: Linking digital assessment of mobility to clinical endpoints to support regulatory acceptance and clinical practice
– IMI2-2017-13-08: Human Tumour Microenvironment Immunoprofiling
– IMI2-2017-13-09: ConcePTION – Continuum of Evidence from Pregnancy Exposures, Reproductive Toxicology and Breastfeeding to Improve Outcomes Now
– IMI2-2017-13-10: Improving the preclinical prediction of adverse effects of pharmaceuticals on the nervous system
– IMI2-2017-13-11: Translational Safety Biomarker Pipeline (TransBioLine): Enabling development and implementation of novel safety biomarkers in clinical trials and diagnosis of disease 
– IMI2-2017-13-12: Pilot programme on a Clinical Compound Bank for Repurposing: Cardiovascular diseases and diabetes 
– IMI2-2017-13-13: Pilot programme on a Clinical Compound Bank for Repurposing: Respiratory diseases 
– IMI2-2017-13-14: Pilot programme on a Clinical Compound Bank for Repurposing: Neurodegenerative diseases
– IMI2-2017-13-15: Pilot programme on a Clinical Compound Bank for Repurposing: Rare/orphan diseases

For more information: click here